No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:51:44.770Z. Latest historical point 2026-03-24. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Fractyl Health, Inc. (GUTS) stock was $4.61 as of Oct 6, 2026, 1:49 PM EDT, up 1.15% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -75.3%
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Biotechnology · Burlington, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.49
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.41
vs Estimate
$-1.64
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GUTS | $60.98M | $4.61 | +1.15% | -75.32% | N/A | N/A | N/A |
| 2KLRS | $61.12M | $2.80 | -1.06% | -57.21% | -81.13% | N/A | vs GUTS |
| 3XLO | $61.28M | $9.32 | +2.31% | -20.35% | N/A | N/A | vs GUTS |
| 4ONCY | $60.04M | $0.60 | +0.22% | -56.57% | -21.00% | -12.54% | vs GUTS |
| 5ACET | $59.36M | $6.35 | -1.85% | -51.37% | -44.24% | N/A | vs GUTS |
| 6CNTB | $59.31M | $0.94 | +4.91% | -39.59% | -47.22% | N/A | vs GUTS |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 6 analysts
Average Price Target
$60.40
+1209.5% upside
Low
$24.00
Current
$4.61
High
$96.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.13 | $-0.12 | $-0.12 | 3 |
| Quarter ending Dec 2026 | $-0.14 | $-0.11 | $-0.09 | 3 |
| Quarter ending Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Quarter ending Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.38 | $-0.34 | $-0.31 | 4 |
| FY 2027 | $-0.49 | $-0.39 | $-0.32 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.65M | $12.43M | $31.88M | 4 |
| FY 2027 | $8.14M | $17.90M | $45.90M | 3 |
